Local Institution

Kobe, Hyōgo 6540026

0 studies enrolling now · 7 studies all time

What they study most

Atrial Fibrillation, Atrial Flutter, Hepatitis C, Hepatitis C Virus (HCV), Non-Small-Cell Lung Carcinoma, Psoriasis, Squamous Cell Carcinoma of the Head and Neck, Thrombosis

Studies at this site

• A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy — Completed
• Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer — Completed
• Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis — Completed
• Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the Chances of Having Additional Strokes or "Mini Strokes" — Completed
• Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation — Completed
• Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy — Completed
• Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3 — Completed